Charles Schwab
SGMO

Charles Schwab’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Charles Schwab’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$581K Buy
2,352,360
+639,029
+37% +$254K ﹤0.01% 3059
2025
Q4 		$720K Buy
1,713,331
+174,333
+11% +$92.4K ﹤0.01% 3036
2025
Q3 		$1.04M Buy
1,538,998
+257,199
+20% +$139K ﹤0.01% 2943
2025
Q2 		$694K Buy
1,281,799
+183,965
+17% +$109K ﹤0.01% 3022
2025
Q1 		$720K Sell
1,097,834
-41,418
-4% -$43.9K ﹤0.01% 2958
2024
Q4 		$1.16M Buy
1,139,252
+35,926
+3% +$65.7K ﹤0.01% 2857
2024
Q3 		$956K Buy
1,103,326
+57,125
+5% +$41.9K ﹤0.01% 2933
2024
Q2 		$375K Sell
1,046,201
-195,930
-16% -$106K ﹤0.01% 3303
2024
Q1 		$832K Buy
1,242,131
+35,252
+3% +$25.6K ﹤0.01% 2852
2023
Q4 		$656K Buy
1,206,879
+15,677
+1% +$7.23K ﹤0.01% 2976
2023
Q3 		$714K Buy
1,191,202
+257,676
+28% +$276K ﹤0.01% 2911
2023
Q2 		$1.21M Sell
933,526
-80,248
-8% -$110K ﹤0.01% 2701
2023
Q1 		$1.78M Sell
1,013,774
-618
-0.1% -$1.76K ﹤0.01% 2555
2022
Q4 		$3.19M Buy
1,014,392
+74,218
+8% +$288K ﹤0.01% 2414
2022
Q3 		$4.61M Buy
940,174
+63,290
+7% +$325K ﹤0.01% 2253
2022
Q2 		$3.63M Sell
876,884
-6,030
-0.7% -$26.1K ﹤0.01% 2328
2022
Q1 		$5.13M Buy
882,914
+33,270
+4% +$198K ﹤0.01% 2266
2021
Q4 		$6.37M Sell
849,644
-89,690
-10% -$779K ﹤0.01% 2229
2021
Q3 		$8.46M Buy
939,334
+26,340
+3% +$260K ﹤0.01% 2104
2021
Q2 		$10.9M Buy
912,994
+24,290
+3% +$275K ﹤0.01% 1951
2021
Q1 		$11.1M Buy
888,704
+38,616
+5% +$520K ﹤0.01% 1900
2020
Q4 		$13.3M Buy
850,088
+74,035
+10% +$867K 0.01% 1682
2020
Q3 		$7.33M Sell
776,053
-354
-0% -$3.83K ﹤0.01% 1869
2020
Q2 		$6.96M Buy
776,407
+48,917
+7% +$454K ﹤0.01% 1865
2020
Q1 		$4.63M Buy
727,490
+10,181
+1% +$75.5K ﹤0.01% 1875
2019
Q4 		$6M Buy
717,309
+20,217
+3% +$186K ﹤0.01% 1931
2019
Q3 		$6.31M Buy
697,092
+20,536
+3% +$230K ﹤0.01% 1856
2019
Q2 		$7.29M Buy
676,556
+86,660
+15% +$922K ﹤0.01% 1785
2019
Q1 		$5.63M Buy
589,896
+24,025
+4% +$245K ﹤0.01% 1927
2018
Q4 		$6.5M Sell
565,871
-23,428
-4% -$291K 0.01% 1743
2018
Q3 		$9.99M Buy
589,299
+23,698
+4% +$360K 0.01% 1644
2018
Q2 		$8.03M Buy
565,601
+71,134
+14% +$1.18M 0.01% 1739
2018
Q1 		$9.39M Buy
494,467
+60,750
+14% +$1.3M 0.01% 1532
2017
Q4 		$7.11M Buy
433,717
+51,801
+14% +$771K 0.01% 1708
2017
Q3 		$5.73M Buy
381,916
+114,623
+43% +$1.27M 0.01% 1809
2017
Q2 		$2.35M Buy
267,293
+1,558
+0.6% +$10K ﹤0.01% 2167
2017
Q1 		$1.38M Buy
265,735
+14,022
+6% +$56.2K ﹤0.01% 2323
2016
Q4 		$768K Buy
251,713
+12,628
+5% +$46K ﹤0.01% 2510
2016
Q3 		$1.11M Sell
239,085
-25,762
-10% -$131K ﹤0.01% 2382
2016
Q2 		$1.53M Buy
264,847
+5,166
+2% +$32.9K ﹤0.01% 2186
2016
Q1 		$1.57M Buy
259,681
+5,681
+2% +$34.1K ﹤0.01% 2170
2015
Q4 		$2.32M Buy
254,000
+52,171
+26% +$402K ﹤0.01% 2006
2015
Q3 		$1.14M Sell
201,829
-14,320
-7% -$118K ﹤0.01% 2342
2015
Q2 		$2.4M Sell
216,149
-111,560
-34% -$1.44M ﹤0.01% 1986
2015
Q1 		$5.14M Sell
327,709
-3,325
-1% -$51.4K 0.01% 1497
2014
Q4 		$5.04M Buy
331,034
+30,000
+10% +$364K 0.01% 1443
2014
Q3 		$3.25M Buy
301,034
+111,606
+59% +$1.46M 0.01% 1685
2014
Q2 		$2.89M Buy
189,428
+17,296
+10% +$249K ﹤0.01% 1766
2014
Q1 		$3.11M Buy
172,132
+10,012
+6% +$193K 0.01% 1683
2013
Q4 		$2.25M Buy
162,120
+23,200
+17% +$267K ﹤0.01% 1846
2013
Q3 		$1.67M Buy
138,920
+14,414
+12% +$143K ﹤0.01% 1961
2013
Q2 		$993K Buy
+124,506
New +$1.09M ﹤0.01% 2164

Other funds holding SGMO

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Charles Schwab's SGMO Position: Q1 2026 in Review

Charles Schwab increased its SANGAMO THERAPEUTICS INC (SGMO) stake by 37% in Q1 2026, buying an estimated $254K and bringing the position to 2,352,360 shares worth $581K. The position accounts for ﹤0.01% of the portfolio, ranked #3059.

Charles Schwab first reported a position in SGMO in Q2 2013 and has held it in 52 quarters since. The position peaked at $13.3M in Q4 2020. 112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.

  • Charles Schwab held 2,352,360 shares of SANGAMO THERAPEUTICS INC worth $581K as of Q1 2026.
  • Charles Schwab bought 639,029 SANGAMO THERAPEUTICS INC shares in Q1 2026, an estimated $254K.
  • SANGAMO THERAPEUTICS INC made up ﹤0.01% of Charles Schwab's portfolio in Q1 2026, its #3059 holding.
  • Charles Schwab first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and has held it in 52 quarters since.
  • Charles Schwab's SANGAMO THERAPEUTICS INC position peaked at $13.3M in Q4 2020.
  • 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.

Based on Charles Schwab's 13F filing for Q1 2026, filed 15 May 2026.